Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6651-6661

  Leung, Joanne ^a,b   Suh, Woong Kyung ^a,b,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER INHIBITION; CANCER TRANSPLANTATION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TUMOR GROWTH; WILD TYPE;

ANIMALS; CELL SEPARATION; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84879123283     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201242     Document Type: Article

References (55)

1. Sica, G. L., I. H. Choi, G. Zhu, K. Tamada, S. D. Wang, H. Tamura, A. I. Chapoval, D. B. Flies, J. Bajorath, and L. Chen. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849-861. (Pubitemid 36776432)
2. Prasad, D. V., S. Richards, X. M. Mai, and C. Dong. 2003. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18: 863-873. (Pubitemid 36776433)
3. Zang, X., P. Loke, J. Kim, K. Murphy, R. Waitz, and J. P. Allison. 2003. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. USA 100: 10388-10392. (Pubitemid 37071888)
4. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203: 871-881.
5. Kryczek, I., S. Wei, L. Zou, G. Zhu, P. Mottram, H. Xu, L. Chen, and W. Zou. 2006. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J. Immunol. 177: 40-44. (Pubitemid 43939113)
6. Choi, I. H., G. Zhu, G. L. Sica, S. E. Strome, J. C. Cheville, J. S. Lau, Y. Zhu, D. B. Flies, K. Tamada, and L. Chen. 2003. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171: 4650-4654. (Pubitemid 37310581)
7. Wang, X., J. Hao, D. L. Metzger, Z. Ao, L. Chen, D. Ou, C. B. Verchere, A. Mui, and G. L. Warnock. 2012. B7-H4 treatment of T cells inhibits ERK, JNK, p38, and AKT activation. PLoS One 7: e28232.
8. Suh, W. K., S. Wang, G. S. Duncan, Y. Miyazaki, E. Cates, T. Walker, B. U. Gajewska, E. Deenick, W. Dawicki, H. Okada, et al. 2006. Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol. Cell. Biol. 26: 6403-6411. (Pubitemid 44277881)
9. Wei, J., P. Loke, X. Zang, and J. P. Allison. 2011. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J. Exp. Med. 208: 1683-1694.
10. Zhu, G., M. M. Augustine, T. Azuma, L. Luo, S. Yao, S. Anand, A. C. Rietz, J. Huang, H. Xu, A. S. Flies, et al. 2009. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 113: 1759-1767.
11. Tringler, B., S. Zhuo, G. Pilkington, K. C. Torkko, M. Singh, M. S. Lucia, D. E. Heinz, J. Papkoff, and K. R. Shroyer. 2005. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11: 1842-1848. (Pubitemid 40471848)
12. Mugler, K. C., M. Singh, B. Tringler, K. C. Torkko, W. Liu, J. Papkoff, and K. R. Shroyer. 2007. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl. Immunohistochem. Mol. Morphol. 15: 363-370. (Pubitemid 350307840)
13. Salceda, S., T. Tang, M. Kmet, A. Munteanu, M. Ghosh, R. Macina, W. Liu, G. Pilkington, and J. Papkoff. 2005. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306: 128-141. (Pubitemid 40692778)
14. Kryczek, I., S. Wei, G. Zhu, L. Myers, P. Mottram, P. Cheng, L. Chen, G. Coukos, and W. Zou. 2007. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67: 8900-8905. (Pubitemid 47437467)
15. Tringler, B., W. Liu, L. Corral, K. C. Torkko, T. Enomoto, S. Davidson, M. S. Lucia, D. E. Heinz, J. Papkoff, and K. R. Shroyer. 2006. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 100: 44-52. (Pubitemid 41815048)
16. Simon, I., Y. Liu, K. L. Krall, N. Urban, R. L. Wolfert, N. W. Kim, and M. W. McIntosh. 2007. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol. Oncol. 106: 112-118. (Pubitemid 46898578)
17. Chen, C., Q. X. Qu, Y. Shen, C. Y. Mu, Y. B. Zhu, X. G. Zhang, and J. A. Huang. 2012. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett. 317: 99-105.
18. Sun, Y., Y. Wang, J. Zhao, M. Gu, R. Giscombe, A. K. Lefvert, and X. Wang. 2006. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151. (Pubitemid 43994236)
19. Zang, X., R. H. Thompson, H. A. Al-Ahmadie, A. M. Serio, V. E. Reuter, J. A. Eastham, P. T. Scardino, P. Sharma, and J. P. Allison. 2007. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. USA 104: 19458-19463.
20. Krambeck, A. E., R. H. Thompson, H. Dong, C. M. Lohse, E. S. Park, S. M. Kuntz, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. Kwon. 2006. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. USA 103: 10391-10396. (Pubitemid 44051177)
21. Jiang, J., Y. Zhu, C. Wu, Y. Shen, W. Wei, L. Chen, X. Zheng, J. Sun, B. Lu, and X. Zhang. 2010. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 59: 1707-1714.
22. Arigami, T., Y. Uenosono, S. Ishigami, T. Hagihara, N. Haraguchi, and S. Natsugoe. 2011. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J. Surg. 35: 2051-2057.
23. Arigami, T., Y. Uenosono, M. Hirata, T. Hagihara, S. Yanagita, S. Ishigami, and S. Natsugoe. 2010. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J. Surg. Oncol. 102: 748-752.
24. Quandt, D., E. Fiedler, D. Boettcher, W. Ch. Marsch, and B. Seliger. 2011. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 17: 3100-3111.
25. Chen, L. J., J. Sun, H. Y. Wu, S. M. Zhou, Y. Tan, M. Tan, B. E. Shan, B. F. Lu, and X. G. Zhang. 2011. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60: 1047-1055.
26. Yi, K. H., and L. Chen. 2009. Fine tuning the immune response through B7-H3 and B7-H4. Immunol. Rev. 229: 145-151.
27. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
28. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-4506.
29. Le, H. K., L. Graham, E. Cha, J. K. Morales, M. H. Manjili, and H. D. Bear. 2009. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9: 900-909.
30. Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
31. Marigo, I., E. Bosio, S. Solito, C. Mesa, A. Fernandez, L. Dolcetti, S. Ugel, N. Sonda, S. Bicciato, E. Falisi, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32: 790-802.
32. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
33. Pulaski, B. A., and S. Ostrand-Rosenberg. 2001. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 20: Unit 20.2.
34. duPre', S. A., D. Redelman, and K. W. Hunter, Jr. 2008. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp. Mol. Pathol. 85: 174-188.
35. Li, H., Y. Han, Q. Guo, M. Zhang, and X. Cao. 2009. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182: 240-249.
36. Hoechst, B., T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, H. Wedemeyer, F. Lehner, M. P. Manns, T. F. Greten, and F. Korangy. 2009. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50: 799-807.
37. Elkabets, M., V. S. Ribeiro, C. A. Dinarello, S. Ostrand-Rosenberg, J. P. Di Santo, R. N. Apte, and C. A. Vosshenrich. 2010. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40: 3347-3357.
38. Corzo, C. A., M. J. Cotter, P. Cheng, F. Cheng, S. Kusmartsev, E. Sotomayor, T. Padhya, T. V. McCaffrey, J. C. McCaffrey, and D. I. Gabrilovich. 2009. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182: 5693-5701.
39. Ugel, S., E. Peranzoni, G. Desantis, M. Chioda, S. Walter, T. Weinschenk, J. C. Ochando, A. Cabrelle, S. Mandruzzato, and V. Bronte. 2012. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2: 628-639.
40. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
41. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111. (Pubitemid 32391043)
42. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907. (Pubitemid 350231320)
43. Maleckar, J. R., and L. A. Sherman. 1987. The composition of the T cell receptor repertoire in nude mice. J. Immunol. 138: 3873-3876. (Pubitemid 17078266)
44. Habu, S., H. Fukui, K. Shimamura, M. Kasai, K. Okumura, and N. Tamaoki. 1983. Role of natural killer cells against tumor growth in nude mice: a brief review. Tokai J. Exp. Clin. Med. 8: 465-468. (Pubitemid 15147447)
45. Zou, W., and L. Chen. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8: 467-477. (Pubitemid 351733418)
46. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
47. Song, H., G. Park, Y. S. Kim, I. Hur, H. Kim, J. W. Ryu, H. K. Lee, D. H. Cho, I. H. Choi, W. J. Lee, and D. Y. Hur. 2008. B7-H4 reverse signaling induces the apoptosis of EBV-transformed B cells through Fas ligand up-regulation. Cancer Lett. 266: 227-237.
48. Park, G. B., H. Song, Y. S. Kim, M. Sung, J. W. Ryu, H. K. Lee, D. H. Cho, D. Kim, W. J. Lee, and D. Y. Hur. 2009. Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 128: 360-368.
49. Flies, D. B., B. J. Sandler, M. Sznol, and L. Chen. 2011. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J. Biol. Med. 84: 409-421.
50. Taube, J. M., R. A. Anders, G. D. Young, H. Xu, R. Sharma, T. L. McMiller, S. Chen, A. P. Klein, D. M. Pardoll, S. L. Topalian, and L. Chen. 2012. Colocalization of inflammatory response with b7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4: 127ra37.
51. Parsa, A. T., J. S. Waldron, A. Panner, C. A. Crane, I. F. Parney, J. J. Barry, K. E. Cachola, J. C. Murray, T. Tihan, M. C. Jensen, et al. 2007. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13: 84-88. (Pubitemid 46067390)
52. Gadiot, J., A. I. Hooijkaas, A. D. Kaiser, H. van Tinteren, H. van Boven, and C. Blank. 2011. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117: 2192-2201.
53. Hino, R., K. Kabashima, Y. Kato, H. Yagi, M. Nakamura, T. Honjo, T. Okazaki, and Y. Tokura. 2010. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116: 1757-1766.
54. Gajewski, T. F. 2012. Cancer immunotherapy. Mol. Oncol. 6: 242-250.
55. Heinonen, H., A. Nieminen, M. Saarela, A. Kallioniemi, J. Klefström, S. Hautaniemi, and O. Monni. 2008. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics 9: 348.